Categories Research Summary, Technology

Nvidia shares jump after Citron Research buys stock

Short-seller Citron Research on Tuesday tweeted that it bought shares of Nvidia Corp (NVDA). Shares of the graphics chipset maker rose about 2.5% at market open on the news.

Shares of Nvidia were down at least 8% in pre-market trade before the news broke.

Last week, Nvidia had announced that the newly launched T4 GPU was adopted faster than any server GPU.

Just two months after its launched, the company claimed that T4 has been featured in 57 separate server designs from various computer makers. Moreover, it has also been implemented in cloud offerings, with the first availability of the T4 for Google Cloud Platform customers.

“We have never before seen such rapid adoption of a datacenter processor,” said Ian Buck, vice president and general manager of Accelerated Computing at NVIDIA.

“Just 60 days after the T4’s launch, it’s now available in the cloud and is supported by a worldwide network of server makers. The T4 gives today’s public and private clouds the performance and efficiency needed for compute-intensive workloads at scale,” he added.

Nvidia's GPU and Tegra Processor businesses revenue trend

However, the stock was suffering post disastrous earnings results. Total reported revenues and the outlook for the fourth quarter fell short of expectations, driving the company’s stock down 16% in the after-hours trading last Thursday, after it announced the results.

Nvidia third quarter 2019 Earnings Infographic

Get access to timely and accurate verbatim transcripts that are published within hours of the event

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top